Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC

NCT00499109 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

275

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Docetaxel
DRUG: Vinorelbine
DRUG: Carboplatin
DRUG: Gemcitabine

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]